

DECLARATION FOR UTILITY PATENT APPLICATION

AS A BELOW-NAMED INVENTOR, I HEREBY DECLARE THAT:

My residence, post-office address, and citizenship are as stated below next to my name.

I believe I am the original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled: MELANOMA ANTIGENIC PEPTIDES, the specification of which is attached hereto unless the following box is checked:

☒ was filed on February 11, 1999 as United States Application Serial No. 09/249,272.

I HEREBY STATE THAT I HAVE REVIEWED AND UNDERSTAND THE CONTENTS OF THE ABOVE-IDENTIFIED SPECIFICATION, INCLUDING THE CLAIMS, AS AMENDED BY ANY AMENDMENT REFERRED TO ABOVE.

I acknowledge the duty to disclose information which is material to the patentability as defined in 37 C.F.R. § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed:

Application No.	Country	Date of Filing (day/month/year)	Priority Claimed?
			<input type="checkbox"/> Yes <input type="checkbox"/> No

I hereby claim benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:


Application Serial No.	Filing Date
60/103,229	10/05/98

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 C.F.R. § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

Application Serial No.	Filing Date	Status
		<input type="checkbox"/> Patented <input type="checkbox"/> Pending <input type="checkbox"/> Abandoned


I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

3/24/99
Date


Name: Charles A. NICOLETTE
Residence: Marlborough, Massachusetts
Citizenship: U.S.A.
Post Office Address: 52 Vega Road, Marlborough, MA 01752

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231, on April 26, 1999.


Jenny Nguyen

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Charles A. NICOLETTE

Serial No.: 09/249,272

Filing Date: February 11, 1999

For: MELANOMA ANTIGENIC PEPTIDES

Examiner: Unassigned

Group Art Unit: 1648

PROSECUTION BY ASSIGNEE AND POWER OF ATTORNEY
UNDER 37 C.F.R. § 3.71

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Genzyme Corporation, the assignee of the entire right, title and interest in this patent application, under 37 C.F.R. § 3.71 hereby appoints:

Mani Adeli (Reg No. 39,585)
Erwin J. Basinski (Reg No. 34,773)
Paula A. Borden (Reg No. 42,344)
Barry E. Bretschneider (Reg No. 28,055)
Alan W. Cannon (Reg No. 34,977)
Robert K. Cerpa (Reg No. 39,933)
Niki D. Cox (Reg No. 42,446)
E. Victor Donahue (Reg No. 35,492)
Sean M. Fitzgerald (Reg No. 42,537)
Hector Gallegos (Reg No. 40,614)
Charles D. Holland (Reg No. 35,196)
Richard D. Jordan (Reg No. 33,519)

Sanjay Bagade (Reg No. 42,280)
Frank P. Becking (Reg No. 42,309)
Sean Brennan (Reg No. 39,917)
Nicholas Buffinger (Reg No. 39,124)
Mark R. Carter (Reg No. 39,131)
Thomas E. Ciotti (Reg No. 21,013)
Raj S. Davé (Reg No. 42,465)
Stephen C. Durant (Reg No. 31,506)
Cheryl L. Franke (Reg No. P-44,113)
Douglas Hodder (Reg No. 41,840)
Madeline I. Johnston (Reg No. 36,174)
Cindy S. Kaplan (Reg No. 40,043)

Ararat Kapouytian (Reg No. 40,044)
Antoinette F. Konski (Reg No. 34,202)
Susan K. Lehnhardt (Reg No. 33,943)
David C. Lundmark (Reg No. 42,815)
Thomas D. Mays (Reg No. 34,524)
Kate H. Murashige (Reg No. 29,959)
Catherine M. Polizzi (Reg No. 40,130)
Robert Saltzberg (Reg No. 36,910)
Debra A. Shetka (Reg No. 33,309)
E. Thomas Wheelock (Reg No. 28,825)
Karen K. Wong (Reg No. P-44,409)

Phanesh B. Koneru (Reg No. 40,053)
Jung-Hua Kuo (Reg No. 41,918)
Wen Liu (Reg No. 32,822)
Harry J. Macey (Reg No. 32,818)
Gladys H. Monroy (Reg No. 32,430)
Dahna S. Pasternak (Reg No. 41,411)
William C. Revelos (Reg No. 42,101)
J. Michael Schiff (Reg No. 40,253)
Thomas G. Wiseman (Reg No. 35,046)
Frank Wu (Reg No. 41,386)

all of Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018, telephone (650) 813-5600, to prosecute this application and transact all matters in the United States Patent and Trademark Office connected therewith, said appointment to be to the exclusion of the inventors and their attorneys in accordance with the provisions of 37 C.F.R. § 3.71, and

Madge R. Kanter (Reg No. 35,211)
Deborah A. Dugan (Reg No. 37,315)
Jennifer Tegfeldt (Reg No. 31,310)
Thomas J. Desrosier (Reg No. 30,168)

Elizabeth Lassen (Reg No. 31,845)
F. Brad Salcedo (Reg. No. 43,076)

whose address is Genzyme Corporation 5 Mountain Road, Framingham, MA 01701-9322, telephone number (508) 872-8400 to prosecute this application and transact all matters in the United States Patent and Trademark Office connected therewith, said appointment to be to the exclusion of the inventors and their attorneys in accordance with the provisions of 37 C.F.R. § 3.71.

Please continue to direct all written communications relative to this application to:

Antoinette F. Konski, Esq.
Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018

Please direct all telephone communications to Antoinette F. Konski at (650) 813-5730.

GENZYME CORPORATION
a corporation

Dated: March 25, 1999



Name: Thomas J. DesRosier

Title: Senior Vice President, Chief Patent Counsel

Address: One Mountain Road
Framingham, MA 01701-9322

ASSIGNMENT SOLE

THIS ASSIGNMENT, by Charles A. NICOLETTE (hereinafter referred to as the assignor), residing at 52 Vega Road, Marlborough, MA 01752, respectively, witnesseth:

WHEREAS, said assignor has invented certain new and useful improvements in MELANOMA ANTIGENIC PEPTIDES, set forth in an application for Letters Patent of the United States, bearing Serial No. 09/249,272 and filed on February 11, 1999; and

WHEREAS, GENZYME CORPORATION, a corporation duly organized under and pursuant to the laws of the Commonwealth of Massachusetts and having a place of business at One Mountain Road, P.O. Box 9322, Framingham, MA 01701-9322 (hereinafter referred to as the assignee) is desirous of acquiring the entire right, title and interest in and to said inventions and said application for Letters Patent of the United States, and in and to any Letters Patent or Patents, United States or foreign, to be obtained therefor and thereon:


NOW, THEREFORE, in consideration of One Dollar (\$1.00) and other good and sufficient consideration, the receipt of which is hereby acknowledged, said assignor have sold, assigned, transferred and set over, and by these presents does sell, assign, transfer and set over, unto said assignee, its successors, legal representatives and assigns, the entire right, title and interest in and to the above-mentioned inventions, application for Letters Patent, and any and all Letters Patent or Patents in the United States of America and all foreign countries which may be granted therefor and thereon, and in and to any and all divisions, continuations and continuations-in-part of said application, or reissues or extensions of said Letters Patent or Patents, and all rights under the International Convention for the Protection of Industrial Property, the same to be held and enjoyed by said assignee, for its own use and the use of its successors, legal representatives and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted, as fully and entirely as the same would have been held and enjoyed by the assignor, had this sale and assignment not been made.

AND for the same consideration, said assignor hereby covenant and agree to and with said assignee its successors, legal representatives and assigns, that, at the time of execution and delivery of these presents, said assignor are the sole and lawful owners of the entire right, title and interest in and to said inventions and the application for Letters Patent above-mentioned, and that the same are unencumbered and that said assignor have good and full right and lawful authority to sell and convey the same in the manner herein set forth.

AND for the same consideration, said assignor hereby covenant and agree to and with said assignee, its successors, legal representatives and assigns, that said assignor will, whenever counsel of said assignee, or the counsel of its successors, legal representatives and assigns, shall advise that any proceeding in connection with said inventions, or said application for Letters Patent, or any proceeding in connection with Letters Patent for said inventions in any country, including interference proceedings, is lawful and desirable, or that any division, continuation or continuation-in-part of any application for Letters Patent or any reissue or extension of any Letters Patent, to be obtained thereon, is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent for said inventions, without charge to said assignee, its successors, legal representatives and assigns, but at the cost and expense of said assignee, its successors, legal representatives and assigns.

AND said assignor hereby request the Commissioner of Patents to issue said Letters Patent of the United States to said assignee as the assignee of said inventions and the Letters Patent to be issued thereon for the sole use of said assignee, its successors, legal representatives and assigns.

3/24/99
Date


Charles A. NICOLETTE